The investigators’ findings suggest dietary interventions may help reduce disease risk.
Two new studies take significant steps toward interventions to reduce cardiac risk in humans by reducing levels of the metabolite TMAO through diet manipulation or targeted therapies.
Findings from a mouse model provide support for a new drug class that acts on gut microbes to reduce platelet responsiveness and thrombosis risk without promoting bleeding or antibiotic resistance.
The physician-scientist draws the American Heart Association’s highest scientific honor for decades of pioneering research in multiple areas.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new report of complementary studies in humans and mice yields the best evidence to date linking gut bacteria to obesity. The findings have therapeutic implications for both obesity and type 2 diabetes.
A new clinical study yields direct evidence of a mechanistic link between TMAO levels and clotting events. And it suggests that TMAO-induced platelet responsiveness can be attenuated by aspirin.
The gut microbe-dependent metabolite TMAO has been linked to increased near-term cardiac events and increased long-term mortality in patients with acute coronary syndrome. Dr. Stan Hazen explains the study.
A cohort study has tied the gut microbial metabolite TMAO to elevated five-year mortality in patients with peripheral artery disease (PAD). Here’s how treatment targeting in PAD may be shaped in response.
Yet another cardiometabolic effect has been linked to the gut microbial metabolite TMAO: increased thrombotic risk stemming from platelet hyperreactivity. The lead Cleveland Clinic researcher discusses the implications.
The year just passed was full of insights and innovations likely to be felt for many years to come. Here are 15 such developments in which Cleveland Clinic staff played key roles.